Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus EPIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus EPIFOAM.
DERMA-SMOOTHE/FS vs EPIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
Epinephrine is a sympathomimetic amine that acts as a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction, bronchodilation, and increased heart rate and contractility.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Not applicable; EPIFOAM is a topical foam containing pramoxine hydrochloride 1% and aluminum acetate, used for hemorrhoidal symptoms. No systemic dosing.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
2-3 hours (terminal elimination half-life); clinically, this supports every 4-6 hour dosing intervals for consistent effect.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Primarily hepatic metabolism to inactive glucuronide conjugates; renal excretion of metabolites accounts for ~80% of elimination, with ~15% biliary/fecal. Less than 5% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid